Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDC-1421 in Adult Patients With ADHD
NCT05202327Phase 2Completed
- Start
- Apr 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of PDC-1421 in attention deficit hyperactivity disorder (ADHD) (3 arms). Primary endpoint: Number of Participants With Improvement >= 40% in ADHD-RS-IV at 8 weeks. Started Apr 2022; status: completed.
02
Drugs
PDC-1421
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT05202327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05202327.